Engineered immune cells take aim at childhood cancer

NCT ID NCT07007117

Ongoing Disease control Sponsor: Stephan Grupp MD PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new type of cell therapy for children with neuroblastoma that has returned or is hard to treat. The therapy uses the patient's own immune cells, which are modified in the lab to recognize and attack a protein called PHOX2B found on neuroblastoma cells. The main goal is to find a safe dose and understand side effects in up to 38 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PHOX2B-targeting CAR T cells (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for children with hard-to-treat neuroblastoma that has come back or not responded to standard therapy.
What could go wrong: This is a very early (phase 1) trial with only 38 participants, so it is primarily testing safety, not effectiveness. The therapy may cause serious side effects or may not work at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-RISK NEUROBLASTOMA REFRACTORY NEUROBLASTOMA RELAPSED NEUROBLASTOMA

Contacts and locations

Locations

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.